Moderna to Present at Upcoming Conferences in May/June 2024
ACCESSWIRE (Mon, 13-May 7:01 AM ET)
Novavax hits 52-week high as Sanofi deal brings upgrades (update)
Seeking Alpha News (Fri, 10-May 12:54 PM ET)
Novavax hits a 52-week high as Sanofi deal prompts J.P. Morgan upgrade
Seeking Alpha News (Fri, 10-May 11:15 AM ET)
Benzinga (Fri, 10-May 9:27 AM ET)
Moderna announces delay in RSV vaccine review in U.S.
Seeking Alpha News (Fri, 10-May 7:17 AM ET)
Moderna Announces Update on Investigational RSV Vaccine
ACCESSWIRE (Fri, 10-May 7:02 AM ET)
Novo Nordisk, Flagship to develop next-generation obesity drugs
Seeking Alpha News (Thu, 9-May 1:22 PM ET)
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
TipRanks (Thu, 9-May 12:30 PM ET)
TipRanks (Thu, 9-May 12:20 PM ET)
Moderna (MRNA) Receives a Buy from Jefferies
TipRanks (Thu, 9-May 7:59 AM ET)
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna trades on the NASDAQ stock market under the symbol MRNA.
As of May 13, 2024, MRNA stock price climbed to $122.52 with 1,011,310 million shares trading.
MRNA has a beta of 1.69, meaning it tends to be more sensitive to market movements. MRNA has a correlation of 0.17 to the broad based SPY ETF.
MRNA has a market cap of $46.91 billion. This is considered a Large Cap stock.
Last quarter Moderna reported $167 million in Revenue and -$3.07 earnings per share. This beat revenue expectation by $76 million and exceeded earnings estimates by $.28.
In the last 3 years, MRNA stock traded as high as $497.49 and as low as $62.55.
The top ETF exchange traded funds that MRNA belongs to (by Net Assets): VTI, VOO, QQQ, VO, SPY.
MRNA stock has underperformed the market in the last year with a return of -6.4%, while SPY returned +27.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRNA shares. However, MRNA has outperformed the market in the last 3 month and 2 week periods, returning +40.2% and +13.5%, while SPY returned +4.3% and +2.5%, respectively. This indicates MRNA has been having a stronger performance recently.
MRNA support price is $114.18 and resistance is $120.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRNA stock will trade within this expected range on the day.